A PI3Kγ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases
Cyclic adenosine monophosphate
Phosphoinositide 3-kinase
DOI:
10.1126/scitranslmed.abl6328
Publication Date:
2022-03-30T17:57:47Z
AUTHORS (46)
ABSTRACT
Cyclic adenosine 3′,5′-monophosphate (cAMP)–elevating agents, such as β 2 -adrenergic receptor (β -AR) agonists and phosphodiesterase (PDE) inhibitors, remain a mainstay in the treatment of obstructive respiratory diseases, conditions characterized by airway constriction, inflammation, mucus hypersecretion. However, their clinical use is limited unwanted side effects because unrestricted cAMP elevation airways distant organs. Here, we identified A-kinase anchoring protein phosphoinositide 3-kinase γ (PI3Kγ) critical regulator discrete signaling microdomain activated -ARs structural inflammatory cells. Displacement PI3Kγ-anchored pool kinase A (PKA) an inhaled, cell-permeable, PI3Kγ mimetic peptide (PI3Kγ MP) inhibited subcortical PDE4B PDE4D safely increased lungs, leading to smooth muscle relaxation reduced neutrophil infiltration murine model asthma. In human bronchial epithelial cells, MP induced unexpected PKA elevations restricted vicinity cystic fibrosis transmembrane conductance (CFTR), ion channel controlling hydration that mutated (CF). promoted phosphorylation wild-type CFTR on serine-737, triggering gating, rescued function F508del-CFTR, most prevalent CF mutant, enhancing existing modulators. These results unveil -AR/cAMP central contraction, immune cell activation, fluid secretion airways, suggesting for compartment-restricted, therapeutic chronic diseases.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (60)
CITATIONS (10)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....